LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7280-7291

  Paglino, Justin C ^a   Ozduman, Koray ^a,b   van den Pol, Anthony N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACIBADEM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC PARVOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FELINE PANLEUKOPENIA VIRUS; GLIA CELL; GLIOBLASTOMA; GLIOMA CELL; H-1 PARVOVIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PHENOTYPIC VARIATION; PORCINE PARVOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; STRAIN DIFFERENCE; TUMOR VIRUS; VIRUS CAPSID; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HOST SPECIFICITY; HUMANS; MICE; NEUROGLIA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PARVOVIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

CANINE PARVOVIRUS; MIRIDAE; PARVOVIRUS; PORCINE PARVOVIRUS; RAT PARVOVIRUS 1A;

EID: 84864114923     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00227-12     Document Type: Article

References (56)

1. Abschuetz A, et al. 2006. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell Tissue Res. 325:423-436.
2. Arruda VR, Xiao W. 2007. It's all about the clothing: capsid domination in the adeno-associated viral vector world. J. Thromb. Haemost. 5:12-15.
3. Arstila P. 1976. Quantitative studies on adsorption, elution, and haemagglutination of vesicular stomatitis virus. Arch. Virol. 51:51-58.
4. Ball-Goodrich LJ, Tattersall P. 1992. Two amino acid substitutions within the capsid are coordinately required for acquisition of fibrotropism by the lymphotropic strain of minute virus of mice. J. Virol. 66:3415-3423.
5. Besselsen DG, Romero MJ, Wagner AM, Henderson KS, Livingston RS. 2006. Identification of novel murine parvovirus strains by epidemiological analysis of naturally infected mice. J. Gen. Virol. 87:1543-1556.
6. Brownstein DG, et al. 1992. The pathogenesis of infection with minute virus of mice depends on expression of the small nonstructural protein NS2 and on the genotype of the allotropic determinants VP1 and VP2. J. Virol. 66:3118-3124.
7. Burnett E, Tattersall P. 2003. Reverse genetic system for the analysis of parvovirus telomeres reveals interactions between transcription factor binding sites in the hairpin stem. J. Virol. 77:8650-8660.
8. Candolfi M, et al. 2010. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc. Natl. Acad. Sci. U. S. A. 107: 20021-20026.
9. Cornelis JJ, et al. 1988. Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J. Virol. 62:1679-1686.
10. Cotmore SF, Tattersall P. 1992. In vivo resolution of circular plasmids containing concatemer junction fragments from minute virus of mice DNA and their subsequent replication as linear molecules. J. Virol. 66: 420-431.
11. Cotmore SF, Tattersall P. 2005. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. J. Virol. 79:2287-2300.
12. Cotmore SF, Tattersall P. 2007. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70:183-232.
13. Daniels GA, et al. 2004. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22:1125-1132.
14. Deleu L, Pujol A, Faisst S, Rommelaere J. 1999. Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J. Virol. 73:3877-3885.
15. Di Piazza M, et al. 2007. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol. 81:4186-4198.
16. Dupont F. 2003. Risk assessment of the use of autonomous parvovirusbased vectors. Curr. Gene Ther. 3:567-582.
17. Dupont F, et al. 2000. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther. 7:790-796.
18. Enderlin M, et al. 2009. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 16: 149-160.
19. Farr GA, Tattersall P. 2004. A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology 323:243-256.
20. Gardiner EM, Tattersall P. 1988. Evidence that developmentally regulated control of gene expression by a parvoviral allotropic determinant is particle mediated. J. Virol. 62:1713-1722.
21. Geletneky K, Herrero y Calle M, Rommelaere J, Schlehofer JR. 2005. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J. Vet. Med. B Infect. Dis. Vet. Public Health 52:327-330.
22. Geletneky K, et al. 2010. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol. 12:804-814.
23. Giese NA, et al. 2002. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 9:432-442.
24. Hallauer C, Kronauer G, Siegl G. 1971. Parvoviruses as contaminants of permanent human cell lines. I. Virus isolation from 1960-1970. Arch. Gesamte Virusforsch. 35:80-90.
25. Hallauer C, Siegl G, Kronauer G. 1972. Parvoviruses as contaminants of permanent human cell lines. Biological properties of the isolated viruses. Arch. Gesamte Virusforsch. 38:366-382.
26. Herrero y Calle M, et al. 2004. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int. J. Cancer 109:76-84.
27. Ishii N, et al. 1999. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9:469-479.
28. Legrand C, Mousset S, Salome N, Rommelaere J. 1992. Cooperation of oncogenes in cell transformation and sensitization to killing by the parvovirus minute virus of mice. J. Gen. Virol. 73:2003-2009.
29. Lichty BD, Power AT, Stojdl DF, Bell JC. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216.
30. Markert JM, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867-874.
31. Moehler MH, et al. 2005. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 16:996-1005.
32. Nister M, et al. 1988. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 48:3910-3918.
33. Op De Beeck A, et al. 2001. NS1- and minute virus of mice-induced cell cycle arrest: involvement of p53 and p21(cip1). J. Virol. 75:11071-11078.
34. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN. 2008. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci. 28:1882-1893.
35. Paglino J, Burnett E, Tattersall P. 2007. Exploring the contribution of distal P4 promoter elements to the oncoselectivity of minute virus of mice. Virology 361:174-184.
36. Paglino J, Tattersall P. 2011. The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwisetransformed human fibroblasts. Virology 416:32-41.
37. Paglino JC, van den Pol AN. 2011. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 85:9346-9358.
38. Paradiso PR. 1981. Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J. Virol. 39:800-807.
39. Parsons DW, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
40. Perros M, et al. 1995. Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in rastransformed cells. J. Virol. 69:5506-5515.
41. Ramasamy R, et al. 2012. Basic fibroblast growth factor modulates cell cycle of human umbilical cord-derived mesenchymal stem cells. Cell Prolif. 45:132-139.
42. Rommelaere J, Cornelis JJ. 1991. Antineoplastic activity of parvoviruses. J. Virol. Methods 33:233-251.
43. Rommelaere J, et al. 2010. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 21:185-195.
44. Rubio MP, Guerra S, Almendral JM. 2001. Genome replication and postencapsidation functions mapping to the nonstructural gene restrict the host range of a murine parvovirus in human cells. J. Virol. 75:11573-11582.
45. Ryder EF, Robakiewicz P. 2001. Statistics for the molecular biologist: group comparisons. Curr. Protoc. Mol. Biol. 67:A.3I.1-A.3I.22. doi: 10.1002/0471142727.mba03is43.
46. Tattersall P, Bratton J. 1983. Reciprocal productive and restrictive viruscell interactions of immunosuppressive and prototype strains of minute virus of mice. J. Virol. 46:944-955.
47. Thompson KA, Yin J. 2010. Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol. J. 7:257. doi: 10.1186/1743-422X-7-257.
48. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507.
49. Westphal M, Lamszus K. 2011. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci. 12:495-508.
50. Wetzel K, et al. 2001. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J. Gene Med. 3:326-337.
51. Wollmann G, Ozduman K, van den Pol AN. 2012. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 18:69-81.
52. Wollmann G, Rogulin V, Simon I, Rose JK, van den Pol AN. 2010. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 84:1563-1573.
53. Wollmann G, Tattersall P, van den Pol AN. 2005. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol. 79:6005-6022.
54. Yeung DE, et al. 1991. Monoclonal antibodies to the major nonstructural nuclear protein of minute virus of mice. Virology 181:35-45.
55. Zeicher M, et al. 2003. Oncoselective parvoviral vector-mediated gene therapy of cancer. Oncol. Res. 13:437-444.
56. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. 2010. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev. 21:103-117.